دورية أكاديمية
أعرض في EDS

Hospital Readmissions Among Persons With Human Immunodeficiency Virus in the United States and Canada, 2005-2018: A Collaboration of Cohort Studies.

التفاصيل البيبلوغرافية
العنوان: Hospital Readmissions Among Persons With Human Immunodeficiency Virus in the United States and Canada, 2005-2018: A Collaboration of Cohort Studies.
المؤلفون: Davy-Mendez T; School of Medicine.; Gillings School of Global Public Health, University of North Carolina at Chapel Hill., Napravnik S; School of Medicine.; Gillings School of Global Public Health, University of North Carolina at Chapel Hill., Hogan BC; Bloomberg School of Public Health., Eron JJ; School of Medicine.; Gillings School of Global Public Health, University of North Carolina at Chapel Hill., Gebo KA; Bloomberg School of Public Health.; School of Medicine, Johns Hopkins University, Baltimore, Maryland., Althoff KN; Bloomberg School of Public Health.; School of Medicine, Johns Hopkins University, Baltimore, Maryland., Moore RD; Bloomberg School of Public Health.; School of Medicine, Johns Hopkins University, Baltimore, Maryland., Silverberg MJ; Division of Research, Kaiser Permanente Northern California, Oakland., Horberg MA; Kaiser Permanente Mid-Atlantic Permanente Research Institute, Rockville, Maryland., Gill MJ; Southern Alberta HIV Clinic, Calgary, Canada., Rebeiro PF; School of Medicine, Vanderbilt University, Nashville, Tennessee., Karris MY; School of Medicine, University of California, San Diego., Klein MB; Faculty of Medicine, McGill University, Montreal, Quebec, Canada., Kitahata MM; School of Medicine, University of Washington, Seattle., Crane HM; School of Medicine, University of Washington, Seattle., Nijhawan A; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas., McGinnis KA; Department of Internal Medicine, Veterans Affairs Connecticut Healthcare, West Haven., Thorne JE; School of Medicine, Johns Hopkins University, Baltimore, Maryland., Lima VD; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada., Bosch RJ; T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts., Colasanti JA; School of Medicine, Emory University, Atlanta, Georgia., Rabkin CS; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland., Lang R; Cumming School of Medicine, University of Calgary, Alberta, Canada., Berry SA; Bloomberg School of Public Health.; School of Medicine, Johns Hopkins University, Baltimore, Maryland.
مؤلفون مشاركون: North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International epidemiology Databases to Evaluate AIDS (IeDEA)
المصدر: The Journal of infectious diseases [J Infect Dis] 2023 Dec 20; Vol. 228 (12), pp. 1699-1708.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
مواضيع طبية MeSH: Patient Readmission* , HIV Infections*/drug therapy , HIV Infections*/epidemiology, Adult ; Male ; Humans ; United States/epidemiology ; HIV ; Cohort Studies ; Canada/epidemiology
مستخلص: Background: Hospital readmission trends for persons with human immunodeficiency virus (PWH) in North America in the context of policy changes, improved antiretroviral therapy (ART), and aging are not well-known. We examined readmissions during 2005-2018 among adult PWH in NA-ACCORD.
Methods: Linear risk regression estimated calendar trends in 30-day readmissions, adjusted for demographics, CD4 count, AIDS history, virologic suppression (<400 copies/mL), and cohort.
Results: We examined 20 189 hospitalizations among 8823 PWH (73% cisgender men, 38% White, 38% Black). PWH hospitalized in 2018 versus 2005 had higher median age (54 vs 44 years), CD4 count (469 vs 274 cells/μL), and virologic suppression (83% vs 49%). Unadjusted 30-day readmissions decreased from 20.1% (95% confidence interval [CI], 17.9%-22.3%) in 2005 to 16.3% (95% CI, 14.1%-18.5%) in 2018. Absolute annual trends were -0.34% (95% CI, -.48% to -.19%) in unadjusted and -0.19% (95% CI, -.35% to -.02%) in adjusted analyses. By index hospitalization reason, there were significant adjusted decreases only for cardiovascular and psychiatric hospitalizations. Readmission reason was most frequently in the same diagnostic category as the index hospitalization.
Conclusions: Readmissions decreased over 2005-2018 but remained higher than the general population's. Significant decreases after adjusting for CD4 count and virologic suppression suggest that factors alongside improved ART contributed to lower readmissions. Efforts are needed to further prevent readmissions in PWH.
Competing Interests: Potential conflicts of interest. K. N. A. reports grants to their institution from NIH; royalties or licenses from Coursera; and consulting fees from NIH and TrioHealth. R. J. B. reports grants to their institution from NIH and support for travel from NIH. J. A. C. reports grants to their institution from NIH and payment or honoraria from Prime Education and Integritas Communications. H. M. C. reports grants to their institution from AHRQ, NIH, and ViiV Healthcare; and participation in a data and safety monitoring board (DSMB) or advisory board for Gilead Sciences, NIH Office of AIDS Research, and ViiV Healthcare. J. J. E. reports grants to their institution from NIH, ViiV Healthcare, Gilead Sciences, and Janssen; consulting fees from ViiV Healthcare, Gilead Sciences, and Merck & Co; and participation on a DSMB or advisory board for TAIMED. K. A. G. reports grants to their institution from the US Department of Defense, NIH, Mental Wellness Foundation, HealthNetwork Foundation, Bloomberg Philanthropies, Defense Health Agency, the State of Maryland, Octapharma, Moriah Fund, and National Center for Advancing Translational Sciences; consulting fees from Spark HealthCare, Teach for America, and Aspen Institute; and participation on a DSMB or advisory board for Pfizer. M. J. G. reports grants to their institution from NIH; and participation on a DSMB or advisor board for Merck & Co, Gilead Sciences, and ViiV Healthcare. B. C. H. reports grants to their institution from NIH. M. A. H. reports grants to their institution from NIH. M. Y. K. reports grants to their institution from Gilead Sciences and ViiV Healthcare; payment or honoraria to their institution from Practice Point Communications CME; leadership in the AIDS Clinical Trials Group (ACTG) Underrepresented Populations Committee (Vice Chair) with payments to their institution; and uncompensated leadership on the Being Alive San Diego Board (member). M. B. K. reports grants to their institution from NIH, ViiV Healthcare, AbbVie, and Gilead Sciences; and consulting fees from ViiV Healthcare, AbbVie, and Gilead Sciences. R. L. reports support for travel from CIHR. V. D. L. reports grants to their institution from CIHR; payment or honoraria from ViiV Healthcare; support for travel from the Conference on Retroviruses and Opportunistic Infections; and participation on a DSMB or advisory board for the Providence Health Care Ethics Board. R. D. M. reports grants to their institution from NIH. S. N. reports grants to their institution from NIH. A. N. reports grants to their institution from Gilead Sciences. P. F. R. reports grants to their institution from NIH and consulting fees from Gilead Sciences and Janssen. J. E. T. reports grants to their institution from the National Eye Institute and ACTG; consulting fees from Gilead Sciences, Canfield, and UpToDate; participation on a DSMB or advisory board for NEI and Tarsier; stock or stock options in Tarsier; and fees for serving as Editor-in-Chief for Ocular Immunology and Inflammation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
(© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
References: Clin Infect Dis. 2020 Oct 23;71(7):1616-1623. (PMID: 31637434)
J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):407-12. (PMID: 26505329)
HIV Med. 2023 Jan;24(1):93-103. (PMID: 35674220)
Int J Epidemiol. 2007 Apr;36(2):294-301. (PMID: 17213214)
PLoS One. 2013 Dec 18;8(12):e81355. (PMID: 24367482)
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):368-75. (PMID: 22240460)
J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):609-16. (PMID: 16284539)
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):349-58. (PMID: 23095935)
J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. (PMID: 14526205)
AIDS Patient Care STDS. 2015 Sep;29(9):465-73. (PMID: 26154066)
JAMA. 2016 Dec 27;316(24):2647-2656. (PMID: 28027367)
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219827615. (PMID: 30760091)
AIDS. 2021 Jul 1;35(8):1229-1239. (PMID: 33710020)
CMAJ. 2018 Sep 24;190(38):E1124-E1133. (PMID: 30249758)
Clin Infect Dis. 2016 Aug 1;63(3):387-95. (PMID: 27143660)
AIDS. 2013 Aug 24;27(13):2059-68. (PMID: 23612008)
J Infect Dis. 2017 Dec 19;216(12):1525-1533. (PMID: 29253205)
HIV Med. 2016 Mar;17(3):167-77. (PMID: 26176492)
Ann Intern Med. 2018 Sep 18;169(6):376-384. (PMID: 30140916)
Ann Intern Med. 2012 Sep 4;157(5):325-35. (PMID: 22944874)
J Gen Intern Med. 2020 Dec;35(12):3581-3590. (PMID: 32556878)
J Infect Dis. 2021 Aug 16;224(4):657-666. (PMID: 34398239)
AIDS. 2010 Jun 19;24(10):1549-59. (PMID: 20502317)
N Engl J Med. 2016 Apr 21;374(16):1543-51. (PMID: 26910198)
J Am Coll Cardiol. 2020 Feb 25;75(7):736-746. (PMID: 32081282)
J Gen Intern Med. 2021 Nov;36(11):3431-3440. (PMID: 33948803)
JAMA Cardiol. 2019 May 1;4(5):444-453. (PMID: 30969316)
J Acquir Immune Defic Syndr. 2022 Jun 1;90(2):161-169. (PMID: 35135975)
J Am Coll Surg. 2014 Oct;219(4):656-63. (PMID: 25159017)
Int J Cardiol. 2019 Mar 1;278:186-191. (PMID: 30579719)
Clin Infect Dis. 2018 Apr 3;66(8):1230-1238. (PMID: 29149237)
CMAJ. 2017 Oct 2;189(39):E1224-E1229. (PMID: 28970260)
J Infect Dis. 2021 Jun 15;223(12):2113-2123. (PMID: 33084891)
J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):330-341. (PMID: 30763292)
معلومات مُعتمدة: U01 DA036935 United States DA NIDA NIH HHS; UM1 AI068634 United States AI NIAID NIH HHS; U01 AI069918 United States AI NIAID NIH HHS; United States NH NIH HHS; K01 HL169020 United States HL NHLBI NIH HHS; P30 AI050410 United States AI NIAID NIH HHS; United States CC CDC HHS; K01 AI093197 United States AI NIAID NIH HHS; F31 AI124794 United States AI NIAID NIH HHS; F31 DA037788 United States DA NIDA NIH HHS; G12 MD007583 United States MD NIMHD NIH HHS; K01 AI093197 United States AI NIAID NIH HHS; K01 AI131895 United States AI NIAID NIH HHS; K23 EY013707 United States EY NEI NIH HHS; K24 AI065298 United States AI NIAID NIH HHS; K24 AI118591 United States AI NIAID NIH HHS; K24 DA000432 United States DA NIDA NIH HHS; KL2 TR000421 United States TR NCATS NIH HHS; N01 CP001004 United States CP NCI NIH HHS; N02 CP055504 United States CP NCI NIH HHS; P30 AI027757 United States AI NIAID NIH HHS; P30 AI027763 United States AI NIAID NIH HHS; P30 AI027767 United States AI NIAID NIH HHS; P30 AI036219 United States AI NIAID NIH HHS; P30 AI050409 United States AI NIAID NIH HHS; P30 AI050410 United States AI NIAID NIH HHS; P30 AI094189 United States AI NIAID NIH HHS; P30 AI110527 United States AI NIAID NIH HHS; P30 MH062246 United States MH NIMH NIH HHS; R01 AA016893 United States AA NIAAA NIH HHS; R01 DA011602 United States DA NIDA NIH HHS; R01 DA012568 United States DA NIDA NIH HHS; R01 AG053100 United States AG NIA NIH HHS; R24 AI067039 United States AI NIAID NIH HHS; R34 DA045592 United States DA NIDA NIH HHS; U01 AA013566 United States AA NIAAA NIH HHS; U01 AA020790 United States AA NIAAA NIH HHS; U01 AI038855 United States AI NIAID NIH HHS; U01 AI038858 United States AI NIAID NIH HHS; U01 AI068636 United States AI NIAID NIH HHS; U01 AI069432 United States AI NIAID NIH HHS; U01 AI069434 United States AI NIAID NIH HHS; U01 DA036297 United States DA NIDA NIH HHS; U10 EY008057 United States EY NEI NIH HHS; U10 EY008052 United States EY NEI NIH HHS; U10 EY008067 United States EY NEI NIH HHS; U01 HL146192 United States HL NHLBI NIH HHS; U01 HL146193 United States HL NHLBI NIH HHS; U01 HL146194 United States HL NHLBI NIH HHS; U01 HL146201 United States HL NHLBI NIH HHS; U01 HL146202 United States HL NHLBI NIH HHS; U01 HL146203 United States HL NHLBI NIH HHS; U01 HL146204 United States HL NHLBI NIH HHS; U01 HL146205 United States HL NHLBI NIH HHS; U01 HL146208 United States HL NHLBI NIH HHS; U01 HL146240 United States HL NHLBI NIH HHS; U01 HL146241 United States HL NHLBI NIH HHS; U01 HL146242 United States HL NHLBI NIH HHS; U01 HL146245 United States HL NHLBI NIH HHS; U01 HL146333 United States HL NHLBI NIH HHS; U24 AA020794 United States AA NIAAA NIH HHS; U54 GM133807 United States GM NIGMS NIH HHS; UL1 RR024131 United States RR NCRR NIH HHS; UL1 TR000004 United States TR NCATS NIH HHS; UL1 TR000083 United States TR NCATS NIH HHS; UL1 TR002378 United States TR NCATS NIH HHS; Z01 CP010176 United States ImNIH Intramural NIH HHS; T32 DA007250 United States DA NIDA NIH HHS; Canada CIHR
فهرسة مساهمة: Investigator: CA Benson; RJ Bosch; GD Kirk; AE Greenberg; AD Castel; AK Monroe; V Marconi; J Colasanti; KH Mayer; C Grasso; RS Hogg; VD Lima; JSG Montaner; K Salters; K Buchacz; J Li; KA Gebo; RD Moore; RD Moore; J Jacobson; MA Horberg; MJ Silverberg; JE Thorne; T Brown; P Tien; G D'Souza; G Smith; M Loutfy; M Gupta; MB Klein; C Rabkin; A Kroch; A Burchell; A Betts; J Lindsay; A Nijhawan; AM Mayor; MJ Gill; JN Martin; SG Deeks; J Li; JT Brooks; MS Saag; MJ Mugavero; G Burkholder; L Bamford; M Karris; JJ Eron; S Napravnik; MM Kitahata; HM Crane; TR Sterling; D Haas; P Rebeiro; M Turner; K McGinnis; A Justice; SJ Gange; JS Lee; B Hogan; E Humes; R Lang; S Coburn; L Gerace; C Stewart
Keywords: HIV; aging; healthcare utilization; hospitalization; readmission
تواريخ الأحداث: Date Created: 20230912 Date Completed: 20231222 Latest Revision: 20240716
رمز التحديث: 20240717
مُعرف محوري في PubMed: PMC10733730
DOI: 10.1093/infdis/jiad396
PMID: 37697938
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-6613
DOI:10.1093/infdis/jiad396